ArticleAmerican heart journal2020
Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial.
Open access · hybridAbstract readClinical Trial Protocol
In one paragraph
Article in American heart journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- A systematic review of enrolment criteria and treatment efficacy for microvascular angina.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Pooled it
- Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial.Circulation · 2024Trial
- Hormonal Modulation in Chronic Coronary Syndrome: From Neurohormonal Activation to Endocrine Targets.Biomedicines · 2026Review
- Functional coronary vascular disease: endotype-based classification, diagnosis, and targeted management.Frontiers in cardiovascular medicine · 2026Review
- Coronary Sinus Reduction for Refractory Angina Caused by Microvascular Dysfunction-A Systematic Review.Journal of clinical medicine · 2025Review
- Treatment options for patients with coronary microvascular dysfunction.Future cardiology · 2025Article
- Current Evidence-Based Treatment of Angina With Nonobstructive Coronary Arteries (ANOCA).Journal of the Society for Cardiovascular Angiography & Interventions · 2025Review
- Expanding diagnostic horizons: the role of multivessel coronary function testing in angina with non-obstructive coronary arteries.Cardiovascular diagnosis and therapy · 2025Article
- Tailored treatment of specific diagnosis improves symptoms and quality of life in patients with myocardial Ischemia and Non-obstructive Coronary Arteries.Scientific reports · 2025Article
- ANOCA, INOCA, MINOCA: The New Frontier of Coronary Syndromes.Journal of cardiovascular development and disease · 2025Review
- Emerging therapeutic frontiers in hypertension management.Frontiers in cardiovascular medicine · 2025Review
- Exploring coronary microvascular dysfunction from functional impairment and structural damage.Frontiers in cardiovascular medicine · 2025Review
- Emerging Pathway to a Precision Medicine Approach for Angina With Nonobstructive Coronary Arteries in Women.JACC. Advances · 2024Review
- Coronary Spasm Testing with Acetylcholine: A Powerful Tool for a Personalized Therapy of Coronary Vasomotor Disorders.Life (Basel, Switzerland) · 2024Review
- Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases (2023 Edition).MedComm · 2023Review
- Current and future strategies for targeting the endothelin pathway in cardiovascular disease.Nature cardiovascular research · 2023Review
- Microvascular arterial disease of the brain and the heart: a shared pathogenesis.QJM : monthly journal of the Association of Physicians · 2023Article
- Efficacy and safety of the endothelin-1 receptor antagonist macitentan in epicardial and microvascular vasospasm; a proof-of-concept study.International journal of cardiology. Heart & vasculature · 2023Article
- Invasive functional testing in the cath lab as a routine investigation in INOCA: pros and cons.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Article
- Global trend and future landscape of coronary microcirculation: A bibliometric and visualized analysis from 1990 to 2021.Heliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 14 institutions in 2 countries.
Andrew J MorrowBritish Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Thomas J FordBritish Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom; University of New South Wales, Sydney, Australia.
Kenneth MangionBritish Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Tushar KotechaRoyal Free Hospital, Royal Free London NHS Foundation Trust London, United Kingdom.
Roby RakhitRoyal Free Hospital, Royal Free London NHS Foundation Trust London, United Kingdom.
Gavin GalaskoLancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom.
Stephen HooleDepartment of Interventional Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom.
Anthony DavenportExperimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom.
Rajesh KharbandaDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, NIHR Oxford Biomedical Research Centre, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.
Vanessa M FerreiraDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, NIHR Oxford Biomedical Research Centre, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Mayooran ShanmuganathanDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, NIHR Oxford Biomedical Research Centre, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Amedeo ChiribiriDivision of Imaging Sciences, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom.
Divaka PereraSchool of Cardiovascular Medicine and Sciences, King's College London, London, United Kingdom.
Haseeb RahmanSchool of Cardiovascular Medicine and Sciences, King's College London, London, United Kingdom.
Jayanth R ArnoldDepartment of Cardiovascular Sciences, Glenfield Hospital, Leicester, United Kingdom.
John P GreenwoodLeeds University and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
Michael FisherLiverpool University and Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
Dirk HusmeierSchool of Mathematics & Statistics, University of Glasgow, Glasgow, United Kingdom.
Nicholas A HillSchool of Mathematics & Statistics, University of Glasgow, Glasgow, United Kingdom.
Xiaoyu LuoSchool of Mathematics & Statistics, University of Glasgow, Glasgow, United Kingdom.
Nicola WilliamsDepartment of Clinical Genetics, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Laura MillerDepartment of Clinical Genetics, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Jill DempsterBritish Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Peter W MacfarlaneBritish Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Paul WelshBritish Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Naveed SattarBritish Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Andrew WhittakerEmerging Innovations Unit, Discovery Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
Alex Mc ConnachieRobertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.
Sandosh PadmanabhanBritish Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Colin BerryBritish Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom. Electronic address: colin.berry@glasgow.ac.uk.
University of Glasgow · GBBritish Heart Foundation · GBKing's College London · GBQueen Elizabeth University Hospital · GBRoyal Free London NHS Foundation Trust · GBUniversity of Oxford · GBAintree University Hospitals NHS Foundation Trust · GBBlackpool Teaching Hospitals NHS Foundation Trust · GBGlenfield Hospital · GBGuy's and St Thomas' NHS Foundation Trust · GBJohn Radcliffe Hospital · GBLeeds Teaching Hospitals NHS Trust · GBPapworth Hospital · GBUniversity of Cambridge · GB
Funding
British Heart Foundation RE/18/6134217Medical Research Council MR/S018905/1
Abstract
Microvascular angina is caused by cardiac small vessel disease, and dysregulation of the endothelin system is implicated. The minor G allele of the non-coding single nucleotide polymorphism (SNP) rs9349379 enhances expression of the endothelin 1 gene in human vascular cells, increasing circulating concentrations of ET-1. The prevalence of this allele is higher in patients with ischemic heart disease. Zibotentan is a potent, selective inhibitor of the ET
Indexed as
Microvascular AnginaPyrrolidinesAdultCardiovascular AgentsDouble-Blind MethodEndothelin Receptor AntagonistsFemaleGenetic TestingHumansMalePolymorphism, Single NucleotidePrecision MedicineRandomized Controlled Trials as TopicReceptor, Endothelin ATreatment OutcomeCardiovascular AgentsEndothelin Receptor AntagonistsPyrrolidinesReceptor, Endothelin AZD4054
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.